FXYD5

FXYD5

FXYD domain containing ion transport regulator 5, also known as FXYD5, is a human gene.cite web | title = Entrez Gene: FXYD5 FXYD domain containing ion transport regulator 5| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=53827| accessdate = ]

PBB_Summary
section_title =
summary_text = This reference sequence was derived from AF161462.1 and ESTs; validated by multiple replicate ESTs and human genomic sequence. This gene encodes a member of a family of small membrane proteins that share a 35-amino acid signature sequence domain, beginning with the sequence PFXYD and containing 7 invariant and 6 highly conserved amino acids. The approved human gene nomenclature for the family is FXYD-domain containing ion transport regulator. Mouse FXYD5 has been termed RIC (Related to Ion Channel). FXYD2, also known as the gamma subunit of the Na,K-ATPase, regulates the properties of that enzyme. FXYD1 (phospholemman), FXYD2 (gamma), FXYD3 (MAT-8), FXYD4 (CHIF), and FXYD5 (RIC) have been shown to induce channel activity in experimental expression systems. Transmembrane topology has been established for two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the C-terminus on the cytoplasmic side of the membrane. This gene product, FXYD5, has not been characterized as a protein. Two transcript variants have been found for this gene, and they are both predicted to encode the same protein. [RefSeq curation by Kathleen J. Sweadner, Ph.D., sweadner@helix.mgh.harvard.edu.] cite web | title = Entrez Gene: FXYD5 FXYD domain containing ion transport regulator 5| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=53827| accessdate = ]

References

Further reading

PBB_Further_reading
citations =
*cite journal | author=Nam JS, Hirohashi S, Wakefield LM |title=Dysadherin: a new player in cancer progression. |journal=Cancer Lett. |volume=255 |issue= 2 |pages= 161–9 |year= 2007 |pmid= 17442482 |doi= 10.1016/j.canlet.2007.02.018
*cite journal | author=Adams MD, Kerlavage AR, Fleischmann RD, "et al." |title=Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence. |journal=Nature |volume=377 |issue= 6547 Suppl |pages= 3–174 |year= 1995 |pmid= 7566098 |doi=
*cite journal | author=Sweadner KJ, Rael E |title=The FXYD gene family of small ion transport regulators or channels: cDNA sequence, protein signature sequence, and expression. |journal=Genomics |volume=68 |issue= 1 |pages= 41–56 |year= 2001 |pmid= 10950925 |doi= 10.1006/geno.2000.6274
*cite journal | author=Zhang QH, Ye M, Wu XY, "et al." |title=Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells. |journal=Genome Res. |volume=10 |issue= 10 |pages= 1546–60 |year= 2001 |pmid= 11042152 |doi=
*cite journal | author=Omasa T, Chen YG, Mantalaris A, Wu JH |title=A cDNA from human bone marrow encoding a protein exhibiting homology to the ATP1gamma1/PLM/MAT8 family of transmembrane proteins. |journal=Biochim. Biophys. Acta |volume=1517 |issue= 2 |pages= 307–10 |year= 2001 |pmid= 11342114 |doi=
*cite journal | author=Ino Y, Gotoh M, Sakamoto M, "et al." |title=Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis. |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=99 |issue= 1 |pages= 365–70 |year= 2002 |pmid= 11756660 |doi= 10.1073/pnas.012425299
*cite journal | author=Strausberg RL, Feingold EA, Grouse LH, "et al." |title=Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=99 |issue= 26 |pages= 16899–903 |year= 2003 |pmid= 12477932 |doi= 10.1073/pnas.242603899
*cite journal | author=Sato H, Ino Y, Miura A, "et al." |title=Dysadherin: expression and clinical significance in thyroid carcinoma. |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue= 9 |pages= 4407–12 |year= 2003 |pmid= 12970317 |doi=
*cite journal | author=Clark HF, Gurney AL, Abaya E, "et al." |title=The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. |journal=Genome Res. |volume=13 |issue= 10 |pages= 2265–70 |year= 2003 |pmid= 12975309 |doi= 10.1101/gr.1293003
*cite journal | author=Shimada Y, Yamasaki S, Hashimoto Y, "et al." |title=Clinical significance of dysadherin expression in gastric cancer patients. |journal=Clin. Cancer Res. |volume=10 |issue= 8 |pages= 2818–23 |year= 2004 |pmid= 15102690 |doi=
*cite journal | author=Shimada Y, Hashimoto Y, Kan T, "et al." |title=Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma. |journal=Oncology |volume=67 |issue= 1 |pages= 73–80 |year= 2004 |pmid= 15459499 |doi= 10.1159/000080289
*cite journal | author=Shimamura T, Yasuda J, Ino Y, "et al." |title=Dysadherin expression facilitates cell motility and metastatic potential of human pancreatic cancer cells. |journal=Cancer Res. |volume=64 |issue= 19 |pages= 6989–95 |year= 2004 |pmid= 15466191 |doi= 10.1158/0008-5472.CAN-04-1166
*cite journal | author=Gerhard DS, Wagner L, Feingold EA, "et al." |title=The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). |journal=Genome Res. |volume=14 |issue= 10B |pages= 2121–7 |year= 2004 |pmid= 15489334 |doi= 10.1101/gr.2596504
*cite journal | author=Wu D, Qiao Y, Kristensen GB, "et al." |title=Prognostic significance of dysadherin expression in cervical squamous cell carcinoma. |journal=Pathol. Oncol. Res. |volume=10 |issue= 4 |pages= 212–8 |year= 2005 |pmid= 15619642 |doi= PAOR.2004.10.4.0212
*cite journal | author=Nishizawa A, Nakanishi Y, Yoshimura K, "et al." |title=Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients. |journal=Cancer |volume=103 |issue= 8 |pages= 1693–700 |year= 2005 |pmid= 15751018 |doi= 10.1002/cncr.20984
*cite journal | author=Batistatou A, Scopa CD, Ravazoula P, "et al." |title=Involvement of dysadherin and E-cadherin in the development of testicular tumours. |journal=Br. J. Cancer |volume=93 |issue= 12 |pages= 1382–7 |year= 2006 |pmid= 16333245 |doi= 10.1038/sj.bjc.6602880
*cite journal | author=Batistatou A, Makrydimas G, Zagorianakou N, "et al." |title=Expression of dysadherin and E-cadherin in trophoblastic tissue in normal and abnormal pregnancies. |journal=Placenta |volume=28 |issue= 5-6 |pages= 590–2 |year= 2007 |pmid= 17084448 |doi= 10.1016/j.placenta.2006.09.004
*cite journal | author=Batistatou A, Peschos D, Tsanou H, "et al." |title=In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin. |journal=Br. J. Cancer |volume=96 |issue= 9 |pages= 1404–8 |year= 2007 |pmid= 17437014 |doi= 10.1038/sj.bjc.6603743

PBB_Controls
update_page = yes
require_manual_inspection = no
update_protein_box = yes
update_summary = yes
update_citations = yes


Wikimedia Foundation. 2010.

Игры ⚽ Нужно решить контрольную?

Look at other dictionaries:

  • FXYD2 — FXYD domain containing ion transport regulator 2, also known as FXYD2, is a human gene.cite web | title = Entrez Gene: FXYD2 FXYD domain containing ion transport regulator 2| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene… …   Wikipedia

  • FXYD1 — FXYD domain containing ion transport regulator 1 (phospholemman), also known as FXYD1, is a human gene.cite web | title = Entrez Gene: FXYD1 FXYD domain containing ion transport regulator 1 (phospholemman)| url =… …   Wikipedia

  • FXYD3 — FXYD domain containing ion transport regulator 3, also known as FXYD3, is a human gene.cite web | title = Entrez Gene: FXYD3 FXYD domain containing ion transport regulator 3| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene… …   Wikipedia

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”